| 单克隆抗体药物在恶性淋巴瘤治疗中的应用 |
| |
| 引用本文： | Niu Y,Shi YK. 单克隆抗体药物在恶性淋巴瘤治疗中的应用[J]. 中国医学科学院学报, 2006, 28(3): 435-441 |
| |
| 作者姓名： | Niu Y Shi YK |
| |
| 作者单位： | 中国医学科学院,中国协和医科大学,肿瘤医院内科,北京,100021 |
| |
| 摘 要： | 单克隆抗体(MoAb)与细胞毒类药物作用机制不同,不良反应无重叠,与化疗有协同作用。传统治疗方案中引入MoAb能够在一定程度上提高恶性淋巴瘤的疗效,且不降低生活质量。MoAb的广泛应用使恶性淋巴瘤的治疗进入了一个新时期,但MoAb的作用机制仍需深入研究,远期不良反应尚未充分了解,不同疾病类型的最佳用药方式需要继续探索。
|
| 关 键 词： | 单克隆抗体 恶性淋巴瘤 治疗 |
| 文章编号： | 1000-503X（2006）03-0435-07 |
| 收稿时间： | 2006-04-19 |
| 修稿时间： | 2006-04-19 |
Monoclonal antibodies in the treatment of malignant lymphoma |
| |
| Niu Yi,Shi Yuan-Kai. Monoclonal antibodies in the treatment of malignant lymphoma[J]. Acta Academiae Medicinae Sinicae, 2006, 28(3): 435-441 |
| |
| Authors: | Niu Yi Shi Yuan-Kai |
| |
| Affiliation: | Department of Medical Oncology, Cancer Hospital, CAMS and PUMC, Beijing 100021, China |
| |
| Abstract: | Monoclonal antibodies (MoAbs) have different mechanism and adverse effects compared with cytotoxic agents. The introduction of MoAbs has improved the treatment potency to malignant lymphoma without decreasing the quality of life . However, there are many questions to be answered: What is the profound mechanism of MoAbs How about their long-term adverse effects What is the best medication pattern in different disease types |
| |
| Keywords: | monoclonal antibody malignant lymphoma treatment |
| 本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录！ |
|
